VIP Deep Dive: How GLP-1 Drugs Quietly Changed Medicine — and What's Coming Next

Five years ago, GLP-1 receptor agonists were niche diabetes medications. They had modest efficacy, unpleasant side effects, and a price that limited use. Then semaglutide and tirzepatide arrived, and the entire trajectory of chronic disease — and the pharmaceutical industry — bent around them.

Today, roughly 50 million Americans are on a GLP-1 drug. The class has reshaped the obesity treatment paradigm, upended the weight-loss industry, prompted airlines to recalculate fuel loads, and forced insurers to rethink coverage for chronic disease. The economic effects have been so large that GLP-1 prescriptions alone now influence U.S. headline inflation.

The Clinical Story

The clinical results have been as striking as the economic ones. In the SELECT trial, semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and pre-existing cardiovascular disease. Kidney outcomes have improved. Liver fat has dropped. Sleep apnea severity has fallen. And now, as reported this week, depression symptoms have improved meaningfully in patients with treatment-resistant disease.